Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Genmab ( (GMAB) ) has issued an announcement.
On June 12, 2025, Genmab A/S announced the grant of 3,320 restricted stock units and 3,636 warrants to its employees. These awards are part of Genmab’s compensation strategy to incentivize and retain talent, with the stock units and warrants vesting after three years. This move underscores Genmab’s commitment to aligning employee interests with company growth, potentially enhancing its competitive position in the biotechnology industry.
The most recent analyst rating on (GMAB) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab’s overall stock score is driven primarily by its strong financial performance, with a robust balance sheet and effective cash flow management. The technical analysis also supports a positive outlook, although the stock may be nearing overbought levels. Valuation metrics are favorable, though the lack of a dividend yield is a minor drawback.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab is an international biotechnology company focused on developing innovative antibody therapeutics to improve the lives of patients. Established in 1999 and headquartered in Copenhagen, Denmark, Genmab has a global presence and a proprietary pipeline that includes bispecific T-cell engagers, antibody-drug conjugates, and next-generation immune checkpoint modulators.
Average Trading Volume: 1,421,678
Technical Sentiment Signal: Sell
Current Market Cap: $14.19B
See more data about GMAB stock on TipRanks’ Stock Analysis page.